Navigation Links
Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
Date:2/4/2008

Tryton's revolutionary Side Branch Stent obtains CE Mark approval based on

unprecedented results in the Tryton 1 (First-in-Man Study) with No

Side-Branch Restenosis in 30 patients.

NEWTON, Mass., Feb. 4 /PRNewswire/ -- Tryton Medical, Inc., the leading developer of stents designed for the definitive treatment bifurcation lesions announced that the company has received CE Mark approval for its Side Branch Stent. The Tryton Side-Branch Stent is a high performance cobalt chromium balloon-expandable coronary stent specifically developed for the complete treatment of the entire spectrum of coronary artery bifurcation disease. Approximately 540,000 annual procedures are performed to address bifurcation lesions, accounting for 20% of all coronary lesions treated. With the exception of Tryton's stent, no dedicated solution exists today that fully addresses these lesions.

The results of the Tryton 1 (First-In-Man) Study were presented by Prof. Patrick Serruys (Erasmus University/Thoraxcenter, Rotterdam NL) and Ralf Mller, M.D. (Helios Heart Centrum, Siegburg DE). When the Tryton cobalt chromium Bare Metal Stent was used with a standard drug eluting stent (Cypher Select, Taxus or Xience V), no side branch restenosis was observed in the 30 patients treated. The initial core laboratory quantitative analysis reported a late loss of 0.27 +/- 0.42 mm in the side branch and 0.12 +/- 0.47 mm in the main vessel. "This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist," said Professor Patrick W. J. C. Serruys, M.D., Head of the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.

"CE Mark will allow us to bring this important technology to market in Europe. A market launch is planned for May in conjunction with EuroPCR 2008," stated H. Richard Davis, CTO, Tryton Medical, Inc.

Every year, over half a million bifurcation coronary lesions are sub-optimally treated as no commercially available optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent -- leaving the side branch vulnerable to thrombosis and restenosis.

About Tryton Medical, Inc.

Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution is commercially available for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent -- leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery. Tryton Medical's Side- Branch Stent(TM) has all the characteristics of a state-of the art workhorse stent, providing proven stent coverage to bifurcation lesions while eliminating the need for provisional stenting. For more information on Tryton Medical, Inc., contact H. Richard Davis at +1-617-332-6060, hrdavis@trytonmedical.com or visit http://www.TrytonMedical.com


'/>"/>
SOURCE Tryton Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
2. Medical University of South Carolina Opens State-of-the-Art Facility
3. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Rosetta Genomics Establishes Medical Advisory Board
5. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer
11. Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising ... been rated one of its top attractions. Fortune 500 companies, such as Illumina, ... a unique and intimate team-building experience. , Each event kicks off with an olive ...
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical ... Office of the National Coordinator for Health IT (ONC) outlining a measurement approach ... data were available when and where it was needed. The organization of health ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... and Drug Administration (FDA) has granted the company’s orphan drug designation request covering ... orphan drug designation granted by the FDA. , Spinocerebellar ataxia is a ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, global image ... Cybernetics corporate branding reflects a results-driven revitalization for a company with a renewed ... components include a crisp, refreshed logo and a new web presence. , “I ...
Breaking Biology Technology:
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):